Business Description
Kymera Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US5015751044
Share Class Description:
KYMR: Ordinary SharesDescription
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.23 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.34 | |||||
| Beneish M-Score | -1.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.8 | |||||
| 3-Year EBITDA Growth Rate | 0.9 | |||||
| 3-Year EPS without NRI Growth Rate | 7.2 | |||||
| 3-Year Book Growth Rate | 3.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -10.88 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.25 | |||||
| 9-Day RSI | 39.45 | |||||
| 14-Day RSI | 40.6 | |||||
| 6-1 Month Momentum % | 40.61 | |||||
| 12-1 Month Momentum % | 75.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.55 | |||||
| Quick Ratio | 8.55 | |||||
| Cash Ratio | 8.27 | |||||
| Days Sales Outstanding | 62.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.7 | |||||
| Shareholder Yield % | -23.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -223 | |||||
| Net Margin % | -191.26 | |||||
| FCF Margin % | -169.25 | |||||
| ROE % | -27.19 | |||||
| ROA % | -21.71 | |||||
| ROIC % | -60.26 | |||||
| ROC (Joel Greenblatt) % | -170.44 | |||||
| ROCE % | -23.73 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.97 | |||||
| PB Ratio | 2.96 | |||||
| Price-to-Tangible-Book | 2.96 | |||||
| EV-to-EBIT | -12.98 | |||||
| EV-to-Forward-EBIT | -8.77 | |||||
| EV-to-EBITDA | -13.48 | |||||
| EV-to-Forward-EBITDA | -9.13 | |||||
| EV-to-Revenue | 24.79 | |||||
| EV-to-Forward-Revenue | 27.74 | |||||
| EV-to-FCF | -14.64 | |||||
| Price-to-Net-Current-Asset-Value | 6.2 | |||||
| Price-to-Net-Cash | 6.48 | |||||
| Earnings Yield (Greenblatt) % | -7.7 | |||||
| FCF Yield % | -5.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KYMR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kymera Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 87.563 | ||
| EPS (TTM) ($) | -2.34 | ||
| Beta | 2.41 | ||
| Volatility % | 72.03 | ||
| 14-Day RSI | 40.6 | ||
| 14-Day ATR ($) | 2.491093 | ||
| 20-Day SMA ($) | 44.05675 | ||
| 12-1 Month Momentum % | 75.02 | ||
| 52-Week Range ($) | 22.35 - 53.27 | ||
| Shares Outstanding (Mil) | 64.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kymera Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kymera Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kymera Therapeutics Inc Frequently Asked Questions
What is Kymera Therapeutics Inc(KYMR)'s stock price today?
The current price of KYMR is $40.82. The 52 week high of KYMR is $53.27 and 52 week low is $22.35.
When is next earnings date of Kymera Therapeutics Inc(KYMR)?
The next earnings date of Kymera Therapeutics Inc(KYMR) is 2025-02-21 Est..
Does Kymera Therapeutics Inc(KYMR) pay dividends? If so, how much?
Kymera Therapeutics Inc(KYMR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers